Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 1,001 shares, a decrease of 80.6% from the July 30th total of 5,152 shares. Based on an average trading volume of 47,320 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.
Straumann Price Performance
SAUHY stock opened at $11.41 on Wednesday. The firm has a 50-day simple moving average of $12.58 and a two-hundred day simple moving average of $11.70. Straumann has a one year low of $9.44 and a one year high of $13.61.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on SAUHY. BMO Capital Markets began coverage on Straumann in a report on Wednesday, July 8th. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft cut shares of Straumann from a “buy” rating to a “hold” rating in a research report on Friday, August 21st. Citigroup restated a “sell” rating on shares of Straumann in a research note on Thursday, July 9th. Morgan Stanley reaffirmed an “underweight” rating on shares of Straumann in a research note on Tuesday, June 30th. Finally, Barclays restated an “overweight” rating on shares of Straumann in a research note on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold”.
About Straumann
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Further Reading
- Five stocks we like better than Straumann
- 5 Stocks to Buy in September Before Wall Street Catches On
- PDD Beat Earnings—So Why Did the Stock Still Fall?
- Tariffs Are Back in Focus: 3 Stocks With a Home-Field Advantage
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
